-
1مؤتمر
المؤلفون: Pedard, Martin, Clavier, Thomas, Mutel, Alexandre, Desrues, Laurence, Lefevre-Scelles, Antoine, Gastaldi, Gioia, El Amki, Mohamad, Dubois, Martine, Melot, A, Curey, Sophie, Gérardin, Emanuel, Proust, François, Compère, Vincent, Castel, Hélène
المساهمون: Cognition, Action, et Plasticité Sensorimotrice Dijon - U1093 (CAPS), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM), Différenciation et communication neuronale et neuroendocrine (DC2N), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Anesthésie et Soins intensifs CHU Rouen, CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service de Neurochirurgie CHU Rouen, Département de Neuroradiologie CHU Rouen, Hôpital de Hautepierre Strasbourg
المصدر: NeuroFrance ; https://normandie-univ.hal.science/hal-02297048Test ; NeuroFrance, May 2019, Marseille, France
مصطلحات موضوعية: ACA = anterior cerebral artery, AUC = area under the curve, CSF = cerebrospinal fluid, DCI = delayed cerebral ischemia, EVD = external ventricular drainage, ICU = intensive care unit, IQR = interquartile range, IRB = institutional review board, MCA = middle cerebral artery, ROC = receiver operating characteristic, SAH = subarachnoid hemorrhage, SAPS II = Simplified Acute Physiology Score II, SE = standard error, UII = urotensin II, UT = urotensin (receptor), VS = vasospasm, WFNS = World Federation of Neurosurgical Societies, cerebral vasospasm, human, intensive care unit, mRS = modified Rankin Scale, mouse, subarachnoid hemorrhage, urotensin II, vascular disorders, [SDV]Life Sciences [q-bio]
الوصف: National audience ; OBJECTIVECerebral vasospasm (VS) is a severe complication of aneurysmal subarachnoid hemorrhage (SAH). Urotensin II (UII) is a potent vasoactive peptide activating the urotensin (UT) receptor, potentially involved in brain vascular pathologies. The authors hypothesized that UII/UT system antagonism with the UT receptor antagonist/biased ligand urantide may be associated with post-SAH VS. The objectives of this study were 2-fold: 1) to leverage an experimental mouse model of SAH with VS in order to study the effect of urotensinergic system antagonism on neurological outcome, and 2) to investigate the association between plasma UII level and symptomatic VS after SAH in human patients.METHODSA mouse model of SAH was used to study the impacts of UII and the UT receptor antagonist/biased ligand urantide on VS and neurological outcome. Then a clinical study was conducted in the setting of a neurosurgical intensive care unit. Plasma UII levels were measured in SAH patients daily for 9 days, starting on the 1st day of hospitalization, and were compared with plasma UII levels in healthy volunteers.RESULTSIn the mouse model, urantide prevented VS as well as SAH-related fine motor coordination impairment. Seventeen patients with SAH and external ventricular drainage were included in the clinical study. The median plasma UII level was 43 pg/ml (IQR 14-80 pg/ml). There was no significant variation in the daily median plasma UII level (median value for the 17 patients) from day 0 to day 8. The median level of plasma UII during the 9 first days post-SAH was higher in patients with symptomatic VS than in patients without VS (77 pg/ml [IQR 33.5-111.5 pg/ml] vs 37 pg/ml [IQR 21-46 pg/ml], p < 0.05). Concerning daily measures of plasma UII levels in VS, non-VS patients, and healthy volunteers, we found a significant difference between SAH patients with VS (median 66 pg/ml [IQR 30-110 pg/ml]) and SAH patients without VS (27 pg/ml [IQR 15-46 pg/ml], p < 0.001) but no significant difference between VS ...
العلاقة: hal-02297048; https://normandie-univ.hal.science/hal-02297048Test
-
2مؤتمر
المؤلفون: Pedard, Martin, Clavier, Thomas, Mutel, Alexandre, Desrues, Laurence, Lefevre-Scelles, Antoine, Gastaldi, Gioia, El Amki, Mohamad, Dubois, Martine, Melot, A, Curey, Sophie, Gérardin, Emanuel, Proust, François, Compère, Vincent, Castel, Hélène
المساهمون: Cognition, Action, et Plasticité Sensorimotrice Dijon - U1093 (CAPS), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM), Différenciation et communication neuronale et neuroendocrine (DC2N), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service Anesthésie et soins intensifs CHU Rouen, CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Service de neurochirurgie CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Département de Neuroradiologie CHU Rouen, Hôpital de Hautepierre Strasbourg
المصدر: NeuroFrance ; https://hal-normandie-univ.archives-ouvertes.fr/hal-02297048Test ; NeuroFrance, May 2019, Marseille, France
مصطلحات موضوعية: cerebral vasospasm, human, intensive care unit, mRS = modified Rankin Scale, mouse, subarachnoid hemorrhage, urotensin II, vascular disorders, SAH = subarachnoid hemorrhage, SAPS II = Simplified Acute Physiology Score II, SE = standard error, UII = urotensin II, UT = urotensin (receptor), VS = vasospasm, WFNS = World Federation of Neurosurgical Societies, ACA = anterior cerebral artery, AUC = area under the curve, CSF = cerebrospinal fluid, DCI = delayed cerebral ischemia, EVD = external ventricular drainage, ICU = intensive care unit, IQR = interquartile range, IRB = institutional review board, MCA = middle cerebral artery, ROC = receiver operating characteristic, [SDV]Life Sciences [q-bio]
الوصف: National audience ; OBJECTIVECerebral vasospasm (VS) is a severe complication of aneurysmal subarachnoid hemorrhage (SAH). Urotensin II (UII) is a potent vasoactive peptide activating the urotensin (UT) receptor, potentially involved in brain vascular pathologies. The authors hypothesized that UII/UT system antagonism with the UT receptor antagonist/biased ligand urantide may be associated with post-SAH VS. The objectives of this study were 2-fold: 1) to leverage an experimental mouse model of SAH with VS in order to study the effect of urotensinergic system antagonism on neurological outcome, and 2) to investigate the association between plasma UII level and symptomatic VS after SAH in human patients.METHODSA mouse model of SAH was used to study the impacts of UII and the UT receptor antagonist/biased ligand urantide on VS and neurological outcome. Then a clinical study was conducted in the setting of a neurosurgical intensive care unit. Plasma UII levels were measured in SAH patients daily for 9 days, starting on the 1st day of hospitalization, and were compared with plasma UII levels in healthy volunteers.RESULTSIn the mouse model, urantide prevented VS as well as SAH-related fine motor coordination impairment. Seventeen patients with SAH and external ventricular drainage were included in the clinical study. The median plasma UII level was 43 pg/ml (IQR 14-80 pg/ml). There was no significant variation in the daily median plasma UII level (median value for the 17 patients) from day 0 to day 8. The median level of plasma UII during the 9 first days post-SAH was higher in patients with symptomatic VS than in patients without VS (77 pg/ml [IQR 33.5-111.5 pg/ml] vs 37 pg/ml [IQR 21-46 pg/ml], p < 0.05). Concerning daily measures of plasma UII levels in VS, non-VS patients, and healthy volunteers, we found a significant difference between SAH patients with VS (median 66 pg/ml [IQR 30-110 pg/ml]) and SAH patients without VS (27 pg/ml [IQR 15-46 pg/ml], p < 0.001) but no significant difference between VS ...
العلاقة: hal-02297048; https://hal-normandie-univ.archives-ouvertes.fr/hal-02297048Test
-
3مؤتمر
المؤلفون: Pedard, Martin, Clavier, Thomas, Mutel, Alexandre, Desrues, Laurence, Lefevre-Scelles, Antoine, Gastaldi, Gioia, El Amki, Mohamad, Dubois, Martine, Melot, A, Curey, Sophie, Gérardin, Emanuel, Proust, François, Compère, Vincent, Castel, Hélène
المساهمون: Cognition, Action, et Plasticité Sensorimotrice Dijon - U1093 (CAPS), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM), Différenciation et communication neuronale et neuroendocrine (DC2N), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Anesthésie et Soins intensifs CHU Rouen, CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service de Neurochirurgie CHU Rouen, Département de Neuroradiologie CHU Rouen, Hôpital de Hautepierre Strasbourg
المصدر: NeuroFrance ; https://normandie-univ.hal.science/hal-02297048Test ; NeuroFrance, May 2019, Marseille, France
مصطلحات موضوعية: ACA = anterior cerebral artery, AUC = area under the curve, CSF = cerebrospinal fluid, DCI = delayed cerebral ischemia, EVD = external ventricular drainage, ICU = intensive care unit, IQR = interquartile range, IRB = institutional review board, MCA = middle cerebral artery, ROC = receiver operating characteristic, SAH = subarachnoid hemorrhage, SAPS II = Simplified Acute Physiology Score II, SE = standard error, UII = urotensin II, UT = urotensin (receptor), VS = vasospasm, WFNS = World Federation of Neurosurgical Societies, cerebral vasospasm, human, intensive care unit, mRS = modified Rankin Scale, mouse, subarachnoid hemorrhage, urotensin II, vascular disorders, [SDV]Life Sciences [q-bio]
الوصف: National audience ; OBJECTIVECerebral vasospasm (VS) is a severe complication of aneurysmal subarachnoid hemorrhage (SAH). Urotensin II (UII) is a potent vasoactive peptide activating the urotensin (UT) receptor, potentially involved in brain vascular pathologies. The authors hypothesized that UII/UT system antagonism with the UT receptor antagonist/biased ligand urantide may be associated with post-SAH VS. The objectives of this study were 2-fold: 1) to leverage an experimental mouse model of SAH with VS in order to study the effect of urotensinergic system antagonism on neurological outcome, and 2) to investigate the association between plasma UII level and symptomatic VS after SAH in human patients.METHODSA mouse model of SAH was used to study the impacts of UII and the UT receptor antagonist/biased ligand urantide on VS and neurological outcome. Then a clinical study was conducted in the setting of a neurosurgical intensive care unit. Plasma UII levels were measured in SAH patients daily for 9 days, starting on the 1st day of hospitalization, and were compared with plasma UII levels in healthy volunteers.RESULTSIn the mouse model, urantide prevented VS as well as SAH-related fine motor coordination impairment. Seventeen patients with SAH and external ventricular drainage were included in the clinical study. The median plasma UII level was 43 pg/ml (IQR 14-80 pg/ml). There was no significant variation in the daily median plasma UII level (median value for the 17 patients) from day 0 to day 8. The median level of plasma UII during the 9 first days post-SAH was higher in patients with symptomatic VS than in patients without VS (77 pg/ml [IQR 33.5-111.5 pg/ml] vs 37 pg/ml [IQR 21-46 pg/ml], p < 0.05). Concerning daily measures of plasma UII levels in VS, non-VS patients, and healthy volunteers, we found a significant difference between SAH patients with VS (median 66 pg/ml [IQR 30-110 pg/ml]) and SAH patients without VS (27 pg/ml [IQR 15-46 pg/ml], p < 0.001) but no significant difference between VS ...
العلاقة: hal-02297048; https://normandie-univ.hal.science/hal-02297048Test
